Mono- versus Bitherapy for Management of HAP/VAP in the ICU
|
|
- Osborne Banks
- 6 years ago
- Views:
Transcription
1 Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag, Astellas
2 Why Combining Two Antibiotics When Treating HAP/VAP? High prevalence of polymicrobial infections and/or infections caused by multidrug-resistant strains Need to start antimicrobial therapy before culture results and to be appropriate ASAP Need to maximize bacterial killing as much as possible High risk of selecting resistant mutants during treatment
3 Monotherapy vs. Bitherapy Since infection is likely to result from highly resistant organisms or to be polymicrobial, combining two antibiotics initially is mandatory in nearly all cases in order to avoid inappropriate treatment.
4 Empiric Antibiotics for HAP ATS-IDSA Joined Guidelines HAP, HCAP or VAP Suspected (All Disease Severity) Late Onset or Risk Factors for Antibiotic - resistant (MDR) Bacteria No Yes Limited Spectrum Antibiotic Therapy Broad Spectrum Antibiotic Therapy For MDR Pathogens
5 Potentially resistant microorganisms in intubated patients with HAP/VAP Martin-Loeches I, et al. Intensive Care Med 2013;39:672-81
6 Why Combining Two Antibiotics When Treating VAP? High prevalence of polymicrobial infections and/or infections caused by multidrug-resistant strains Need to start antimicrobial therapy before culture results and to be appropriate ASAP Need to maximize bacterial killing as much as possible High risk of selecting resistant mutants during treatment
7 Appropriateness of antimicrobial therapy and survival in 5715 patients with septic shock Kumar et al. Chest 2009;136:
8 Selection of initial antimicrobial therapy is difficult Appropriateness of antimicrobial therapy and survival in 5715 patients with septic shock Kumar et al. Chest 2009;136: % 76%
9 Pathogens Associated with Inappropriate Initial Therapy in Patients with VAP 100% 80% 60% 40% 20% 0% Alvarez-Lerma Kollef Luna Rello Pseudomonas Acinetobacter MR S. aureus BLSE-producing Enterobacteriaceae Others
10 Klebsiella pneumoniae: proportion of invasive isolates with combined resistance to 3 rd gen. cephalosporins, FQ and AG in 2011 European Antimicrobial Resistance Surveillance Network (EARS-Net)
11 P. aeruginosa: proportion of invasive isolates with combined resistance to 3 or more antibiotic classes in 2011 European Antimicrobial Resistance Surveillance Network (EARS-Net)
12 Emerging KPC and VIM carbapenemases in Klebsiella Greece Clone with KPC replacing epidemic of bla VIM plasmids VIM KPC Widespread >1 outbreak 1 outbreak Sporadic Grundmann et al. Euro Surveill 2010;15:19711; ARMRL, data on file;
13 P. aeruginosa VAP: Importance of Initial Treatment Combining Two Effective Antibiotics in 183 Episodes Appropriate initial treatment, % Mortality, % Garnacho-Montero et al.ccm P < P = Monotherapy (38/67) Combination (105/116) 0 Monotherapy (34/67) Combination (43/116)
14 Appropriateness of Antibiotic Therapy in Patients Receiving or not an AG as Empirical Therapy Martinez JA, et al. AAC 2010;54: Microorganism Combination Beta-lactam OR (95% CI) P No./total no. (%) No./total no. (%) Non-ESBL E. coli 242/248 (98) 2,454/2,489 (99) 0.6 ( ) 0.3 ESBL E. coli 21/28 (75) 62/122 (51) 2.9 ( ) 0.02 Non-ESBL Klebsiella 62/63 (98) 393/420 (94) 4 ( ) 0.2 ESBL K. pn. 18/20 (90) 38/63 (60) 2 ( ) 0.01 P. mirabilis 10/10 (100) 116/118 (98) 1 Salmonella spp. 15/15 (100) 108/109 (99) 1 AmpC organisms 78/82 (95) 258/326 (79) 5.1 (1.8-20) P. aeruginosa 133/143 (93) 201/319 (63) 7.8 (3.8-16) <.0001 Other NF-GNB 24/51 (47) 53/105 (51) 0.9 ( ) 0.7 Miscellaneous 18/18 (100) 105/114 (92) 0.4
15 Antimicrobial Treatment of Hospital-acquired Pneumonia o In patients with HAP/VAP and risk factors for MDR should an aminoglycoside or a fluoroquinolone be selected when a regimen combining two antibiotics is used to improve initial therapy efficacy?
16 Escherichia coli: percentage of invasive isolates with resistance to aminoglycosides or quinolones, 2011 European Antimicrobial Resistance Surveillance Network (EARS-Net)
17 Klebsiella pneumoniae: proportion of invasive isolates resistant to AG or fluoroquinolones in 2011 European Antimicrobial Resistance Surveillance Network (EARS-Net) European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2011.
18 P. aeruginosa: proportion of invasive isolates with resistance to AG or FQ in 2011 European Antimicrobial Resistance Surveillance Network (EARS-Net) European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2011.
19 Why Combining Two Antibiotics When Treating VAP? High prevalence of polymicrobial infections and/or infections caused by multidrug-resistant strains Need to start antimicrobial therapy before culture results and to be appropriate ASAP Need to maximize bacterial killing as much as possible High risk of selecting resistant mutants during treatment
20 Mono- vs. Bi-therapy for Treating HAP/VAP There is no clinical benefit associated with a regimen combining two antibiotics when the infection is mild or moderate, and/or caused by a microorganism easily targeted by a very effective antimicrobial agent penetrating well into the lung.
21 A survival benefit of combination antibiotic therapy for sepsis and septic shock is contingent only on the risk of death: A metaanalytic/meta-regression study Kumar A, et al. Crit Care med 2010;38: Non-RCT, n=44) RCT, n=12) >25% >25%
22 Randomized trial of combination versus monotherapy for the empiric treatment of suspected VAP Heyland DK, et al. Crit Care Med 2008;36: o 740 patients who developed VAP. Patients known to be colonized or infected with Pseudomonas or MRSA or who were immunocompromised were excluded. o Patients were allocated to receive meropenem (1 g q8 h) and ciprofloxacin (400 mg q12 h) or meropenem alone. o There was no difference in 28-day mortality between the two groups (RR 1.05, 95% Cl , p 0.74).
23 Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem in Patients With Severe Sepsis: A Randomized Trial Brunkhorst FM, et al. JAMA. 2012;307:2390-9
24 Empirical Treatment With Moxifloxacin and Meropenem vs Meropenem in Patients With Severe Sepsis: A Randomized Trial Brunkhorst FM, et al. JAMA. 2012;307:2390-9
25 Clinical implications of betalactam AG synergism: systematic review of randomised trials Marcus R, et al. Intern J Antimicrob Agents 2011;37: All-cause mortality was similar with monotherapy versus combination therapy [risk ratio = 0.96, 95% CI , 28 trials, 3756 episodes] Clinical failure was not significantly different (RR = 0.88, 95% CI , 27 trials, 2500 episodes) Combination therapy resulted in a significantly higher incidence of adverse events, mainly nephrotoxicity Overall, no clinical benefit was found for the use of a betalactam with an AG compared with a betalactam alone
26 Mono- vs. Bi-therapy for Treating HAP/VAP In contrast, when the infection is severe, associated with severe sepsis or septic shock, and/or caused by a difficult-to-treat microorganism, such as P. aeruginosa or NF-GNB, combining two effective antimicrobial agents is a superior option, at least initially.
27 Effect of Antimicrobial Therapy on Survival of Neutropenic Rats Challenged Intraperitoneally with 1.7x10 8 cfu of P. aeruginosa Johnson and Thompson, Am J Med 1986
28 o o o Randomized trial of combination versus monotherapy for the empiric treatment of suspected VAP Heyland DK, et al. Crit Care Med 2008;36: There was no difference in 28-day mortality between the two groups (RR 1.05, 95% Cl: ). Duration of ICU and hospital stay, clinical and microbiological treatment response, emergence of antibiotic-resistant bacteria, and isolation of C. difficile were also similar in the two groups. In patients with MDR GNB infection (n=56), the adequacy of initial antibiotics (84% vs. 19%, p <.001) and microbiological eradication of infecting organisms (64% vs. 29%, p<0.05) were higher in the combination group.
29 Subgroup analysis of patients with difficult-to-treat GNB Heyland DK, et al. Crit Care Med 2008;36:737 44
30 Adjusted Cox proportional hazards of mortality associated with combination antibiotic therapy of septic shock Kumar A, et al. Crit Care Med 2010; 38:
31 Relations between Both Empirical and Definitive Antimicrobial Therapy and Mortality in 98 P.aeruginosa Bacteremia Chamot et al. Antimicrob Agents Chemother. 2003;47: CHARACTERISTIC Empirical antimicrobial Rx. Adequate combination Adequate monotherapy Inadequate therapy Definitive antimicrobial Rx. Adequate combination Adequate monotherapy Inadequate therapy HAZARD RATIO % CI P VALUE
32 Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an AG or a FQ for P. aeruginosa Bacteremia Bliziotis IA, et al. PLoS One. 2011;6(10):e26470 o Retrospective cohort study of 54 episodes of Pa BSI from 3 tertiary hospitals (2 in Greece and 1 in Italy). o Treatment success was higher with combination therapy (85%) compared to beta-lactam monotherapy (65%), however not statistically significantly [OR 3.1; 95% CI , p = 0.1]. o All-cause mortality did not differ significantly between combination therapy [19%] and monotherapy [42%], p = o Only Charlson comorbidity index was associated with excess mortality (p = 0.03).
33 The growing challenge of multidrug resistant GNB Carbapenem-resistant Klesiella pneumoniae (VIM+, KPC+, NDM-1+) Pseudomonas aeruginosa (Stably derepressed chromosomal AmpC enzyme, OprD downregulated, VIM+) Acinetobacter baumannii (VIM+, OXA+, Efflux pumps+, NDM-1+)
34 Doripenem combined with colistin is bactericidal and synergistic against colistin-r, carbapenemase-producing K. pneumoniae Jernigan MG, et al. AAC, Published Ahead of Print 19 March Colistin Colistin + doripenem
35 Why Combining Two Antibiotics When Treating VAP? High prevalence of polymicrobial infections and/or infections caused by multidrug-resistant strains Need to start antimicrobial therapy before culture results and to be appropriate ASAP Need to maximize bacterial killing as much as possible High risk of selecting resistant mutants during treatment
36 Impact of Different Antimicrobial Regimens on Resistance Emergence in an in-vitro Model of P. aeruginosa Infection Louie A, et al. Antimicrob Agents Chemother 2010;54(6): Total population Wild-type PAO1 strain Imipenem 1g q8h, Doripenem 1h infusion 1g q8h, 4h infusion Total population Resistant population Resistant population
37 Relationship Between Development of Resistance and Antimicrobial PK/PD in Patients with LRT Infection Thomas JK, et al. Antimicrob Agents Chemother. 1998;42: AUC 0-24 /MIC ratio > 100 AUC 0-24 /MIC ratio < 100 Type 1 beta-lact. organisms betalactam monotherapy
38 Limited Value of Combination Therapy in Patients with Severe Infection Paul et al. BMJ 2004; 328: 668 Meta-analysis of beta-lactam monotherapy vs. beta-lactam/aminoglycoside combination for severe infection 64 randomized trials, non-neutropenic,7586 patients No difference in mortality (RR for monorx. 0.90) No differences in clinical and bacteriologic failures (RR=0.87 and 0.86) No advantage for P. aeruginosa infection (426 pts) No difference in emergence of resistance Significantly less nephrotoxicity (RR =0.36)
39 Campaign to Prevent Antimicrobial Resistance in Healthcare Settings Selection for antimicrobial-resistant Strains Resistant Strains Rare Antimicrobial Exposure Resistant Strains Dominant
40 Mono- vs. combination therapy for treating HAP/VAP Combining a broad-spectrum betalactam and an aminoglycoside for the first 2-3 days of therapy improve appropriateness and efficacy of initial therapy in patients with risk factors for MDR. Such a strategy should be coupled with a strong commitment to de-escalate once culture results are available, i.e., stopping AG and restricting broad-spectrum betalactams to infection caused by pathogens only susceptible to these agents. Whether or not using a combination therapy after days 2-3 in patients infected with NF-GNB pathogens remains to be elucidated.
Successful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationPharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens
Pharmacodynamics as an Approach to Optimizing Therapy Against Problem Pathogens Jared L. Crandon, Pharm.D., BCPS Associate Director, Clinical and Experimental Pharmacology Center for Anti-Infective Research
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationOther β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL
Other β-lactamase Inhibitor (BLI) Combinations: Focus on VNRX-5133, WCK 5222 and ETX2514SUL David P. Nicolau, PharmD, FCCP, FIDSA Director, Center for Anti-Infective Research and Development Hartford Hospital
More informationDR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA
DR. MICHAEL A. BORG DIRECTOR OF INFECTION PREVENTION & CONTROL MATER DEI HOSPITAL - MALTA The good old days The dread (of) infections that used to rage through the whole communities is muted Their retreat
More information10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017
10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationLearning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of
More informationA snapshot of polymyxin use around the world South America
A snapshot of polymyxin use around the world South America Alexandre P. Zavascki Infectious Diseases Service, Hospital de Clínicas de Porto Alegre Medical School, Federal University of Rio Grande do Sul
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationDissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters
Dissecting the epidemiology of resistant Enterobacteriaceae and non-fermenters Jon Otter, PhD Centre for Clinical Infection and Diagnostics Research (CIDR), King's College London & Guy's and St. Thomas'
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationManagement of hospital-acquired acquired pneumonia in the Asian Pacific region
Management of hospital-acquired acquired pneumonia in the Asian Pacific region Jae-Hoon Song, MD, PhD Samsung Medical Center Asian Network for Surveillance of Resistant Pathogens (ANSORP) Asian-Pacific
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationCombining antibiotics: when does it make sense and why? José Manuel Pereira
Combining antibiotics: when does it make sense and why? José Manuel Pereira Serviço de Medicina Intensiva do Centro Hospitalar S. João, EPE Faculdade de Medicina da Universidade do Porto Grupo de Infecção
More informationETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections
ETX2514SUL (sulbactam/etx2514) for the treatment of Acinetobacter baumannii infections Robin Isaacs Chief Medical Officer, Entasis Therapeutics Dr. Isaacs is a full-time employee of Entasis Therapeutics.
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationIs biocide resistance already a clinical problem?
Is biocide resistance already a clinical problem? Stephan Harbarth, MD MS University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland Important points Biocide resistance exists Antibiotic
More informationPresenter: Ombeva Malande. Red Cross Children's Hospital Paed ID /University of Cape Town Friday 6 November 2015: Session:- Paediatric ID Update
Emergence of invasive Carbapenem Resistant Enterobacteriaceae CRE infection at RCWMCH Ombeva Oliver Malande, Annerie du Plessis, Colleen Bamford, Brian Eley Presenter: Ombeva Malande Red Cross Children's
More informationWhy should we care about multi-resistant bacteria? Clinical impact and
Why should we care about multi-resistant bacteria? Clinical impact and public health implications Prof. Stephan Harbarth Infection Control Program Geneva, Switzerland and Ebola (in 2014/2015) Increased
More informationInfectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
More informationTrea%ng Sepsis in 2016 Are the Big Guns Losing the War?
Trea%ng Sepsis in 2016 Are the Big Guns Losing the War? ERIC HODGSON FCA (Crit Care) Inkosi Albert Luthuli Central Hospital & NELSON R MANDELA SCHOOL OF MEDICINE DURBAN, KZN Declaration Advisory boards
More informationSummary of the latest data on antibiotic consumption in the European Union
Summary of the latest data on antibiotic consumption in the European Union ESAC-Net surveillance data November 2016 Provision of reliable and comparable national antimicrobial consumption data is a prerequisite
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationThe role of carbapenems in the hospital
The role of carbapenems in the hospital Matteo Bassetti, MD, PhD Infectious Diseases Division Santa Maria Misericordia University Hospital Udine, Italy Rationale for Antibiotic Optimizaton: Balancing The
More informationHigh-Risk MDR clones news in treatment
Ferrara, 20 giugno 2013 High-Risk MDR clones news in treatment Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Characteristics and determinants of outcome of hospital-acquired
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationAntimicrobial resistance (EARS-Net)
SURVEILLANCE REPORT Annual Epidemiological Report for 2014 Antimicrobial resistance (EARS-Net) Key facts Over the last four years (2011 to 2014), the percentages of Klebsiella pneumoniae resistant to fluoroquinolones,
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationAntibiotics 201: Gramnegatives
Antibiotics 201: Gramnegatives B. Joseph Guglielmo, Pharm.D. Professor and Dean School of Pharmacy University of California San Francisco Disclosures No potential conflicts of interest. 1 A 77 year old
More information2016 Updates to the Hospital Acquired- and Ventilator Associated-Pneumonia Guidelines
2016 Updates to the Hospital Acquired- and Ventilator Associated-Pneumonia Guidelines Janessa M. Smith, PharmD, BCPS Clinical Pharmacy Specialist, Infectious Diseases The Johns Hopkins Hospital Objectives
More informationPRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE
PRACTIC GUIDELINES for APPROPRIATE ANTIBIOTICS USE Global Alliance for Infection in Surgery World Society of Emergency Surgery (WSES) and not only!! Aims - 1 Rationalize the risk of antibiotics overuse
More informationMDR Acinetobacter baumannii. Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta
MDR Acinetobacter baumannii Has the post antibiotic era arrived? Dr. Michael A. Borg Infection Control Dept Mater Dei Hospital Malta 1 The Armageddon recipe Transmissible organism with prolonged environmental
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationManagement of Infections with Multi-drug Resistance Bacteria การร กษาการต ดเช อแบคท เร ยด อยา
Management of Infections with Multi-drug Resistance Bacteria การร กษาการต ดเช อแบคท เร ยด อยา รองศาสตราจารย แพทย หญ งศศ โสภ ณ เก ยรต บ รณก ล คณะแพทยศาสตร โรงพยาบาลรามาธ บด Sasisopin Kiertiburanakul, MD,
More informationBacterial infections complicating cirrhosis
PHC www.aphc.info Bacterial infections complicating cirrhosis P. Angeli, Dept. of Medicine, Unit of Internal Medicine and Hepatology (), University of Padova (Italy) pangeli@unipd.it Agenda Epidemiology
More information5/4/2018. Multidrug Resistant Organisms (MDROs) Objectives. Outline. Define a multi-drug resistant organism (MDRO)
Multidrug Resistant Organisms (MDROs) Kasturi Shrestha, M.D. 05/11/2018 Objectives Define a multi-drug resistant organism (MDRO) Identify most challenging MDROs in healthcare Identify reasons for health
More informationMultidrug-resistant bacteria: what is the threat?
INFECTIOUS DISEASE COMPLICATIONS ENCOUNTERED BY THE PRACTICING HEMATOLOGIST Multidrug-resistant bacteria: what is the threat? Matteo Bassetti 1 and Elda Righi 1 1 Infectious Diseases Division, Santa Maria
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationBest Practices: Goals of Antimicrobial Stewardship
Best Practices: Goals of Antimicrobial Stewardship Gail Scully, M.D, M.P.H. and Elizabeth Radigan, PharmD, BCPS UMass Memorial Medical Center Division of Infectious Disease Department of Medicine September
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationDe-escalation as a Critical Strategy in Acute Care. by author. Prof Bojana Beović, MD, PhD
De-escalation as a Critical Strategy in Acute Care Prof Bojana Beović, MD, PhD University Medical Centre Ljubljana Faculty of Medicine, University of Ljubljana Ljubljana, Slovenia Disclosures Speaker for
More informationManagement of hospital-acquired pneumonia and ventilator-associated pneumonia: an ERS/ESICM/ESCMID/ ALAT guideline
ERS pocket guidelines Management of hospital-acquired pneumonia and ventilator-associated pneumonia: an ERS/ESICM/ESCMID/ ALAT guideline From the Task Force for the Management of Hospital-acquired Pneumonia
More informationDoripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities
REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More informationAntimicrobial de-escalation in the ICU
Antimicrobial de-escalation in the ICU A FOCUS ON EVIDENCE-BASED STRATEGIES Dave Leedahl, PharmD, BCPS-AQ ID, BCCCP Pharmacy Clinical Manager Sanford Health Fargo, ND, USA I have no conflicts of interest
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationContribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections
Contribution of pharmacokinetic and pharmacodynamic parameters of antibiotics in the treatment of resistant bacterial infections Francois JEHL Laboratory of Clinical Microbiology University Hospital Strasbourg
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationTreatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia
SUPPLEMENT ARTICLE Treatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia Antoni Torres, Miquel Ferrer, and Joan Ramón Badia Pneumology Department, Clinic Institute
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationGORILLACILLINS IN THE ICU:
Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver
More informationDifficult to Treat Bacterial Infections: Have we reached a Dead End?
Difficult to Treat Bacterial Infections: Have we reached a Dead End? Dr. George M. Varghese MD, DNB, DTMH, FRCP, FIDSA Department of Infectious Diseases Christian Medical College, Vellore, India Outline
More informationETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens
ETX2514: Responding to the global threat of nosocomial multidrug and extremely drug resistant Gram-negative pathogens Ruben Tommasi, PhD Chief Scientific Officer ECCMID 2017 April 24, 2017 Vienna, Austria
More informationImagine. Multi-Drug Resistant Superbugs- What s the Big Deal? A World. Without Antibiotics. Where Simple Infections can be Life Threatening
Multi-Drug Resistant Superbugs- What s the Big Deal? Toni Biasi, RN MSN MPH CIC Infection Prevention Indiana University Health Imagine A World Without Antibiotics A World Where Simple Infections can be
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationMRSA ventilatorassociated
MRSA ventilatorassociated pneumonia Jean Chastre, M.D. www.reamedpitie.com Conflicts of interest Consulting or lecture fees: Medimmune/Astrazeneca, Bayer, Pfizer, Arsanis, Cubist/Merck, Basilea, Aridis,
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More information(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE
(DRAFT) RECOMMENDATIONS FOR THE CONTROL OF MULTI-DRUG RESISTANT GRAM-NEGATIVES: CARBAPENEM RESISTANT ENTEROBACTERIACEAE John Ferguson (Hunter New England, NSW) on behalf of MRGN Task Force Acknowledgement
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationFIS Resistance Surveillance: The UK Landscape. Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance
FIS 2013 Resistance Surveillance: The UK Landscape Alasdair MacGowan Chair BSAC Working Party on Antimicrobial Resistance Surveillance A statement of the obvious Good quality surveillance data on resistant
More informationCollege of Medicine, Chang Gung University, Taoyuan, Taiwan. Abstract
DOI 10.6314/JIMT.2016.27(2).05 2016 27 89-96 Combination Antibiotics for Gram-negative Bacteria in Patients with Healthcare-associated or Hospital-acquired Pneumonia with Severe Sepsis or Septic Shock
More informationResistant Gram-negative Bacteria
Introduction Antibiotic-resistant bacteria aren t new. But gram-negative bacteria, like Enterobacteriaceae, are becoming more resistant to our last-line antibiotics. Some people are calling these bacteria
More informationHuman health impacts of antibiotic use in animal agriculture
Human health impacts of antibiotic use in animal agriculture Beliefs, opinions, and evidence Peter Davies BVSc, PhD College of Veterinary Medicine, University of Minnesota, USA Terminology Antibiotic Compound
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationTaiwan Crit. Care Med.2009;10: %
2008 30% 2008 2008 2004 813 386 07-346-8339 E-mail srwann@vghks.gov.tw 66 30% 2008 1 2008 2008 Intensive Care Med (2008)34:17-60 67 2 3 C activated protein C 4 5,6 65% JAMA 1995;273(2):117-23 Circulation,
More information48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.
48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin
More informationSummary of unmet need guidance and statistical challenges
Summary of unmet need guidance and statistical challenges Daniel B. Rubin, PhD Statistical Reviewer Division of Biometrics IV Office of Biostatistics, CDER, FDA 1 Disclaimer This presentation reflects
More information9.4 Antimicrobial Resistance
9.4 Antimicrobial Resistance a) Key Pathogens causing Bloodstream Infections 2016 Summary Estimated 99% coverage of the Irish population versus 97% in 2015 There were 3,057 reports of invasive E. coli
More informationAerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune
Original article Aerobic bacterial infections in a burns unit of Sassoon General Hospital, Pune Patil P, Joshi S, Bharadwaj R. Department of Microbiology, B.J. Medical College, Pune, India. Corresponding
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationReceived 23 May 2004/Returned for modification 31 August 2004/Accepted 11 October 2004
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 2005, p. 760 766 Vol. 49, No. 2 0066-4804/05/$08.00 0 doi:10.1128/aac.49.2.760 766.2005 Copyright 2005, American Society for Microbiology. All Rights Reserved.
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More information